Search

Your search keyword '"Eyjolfsdottir B"' showing total 2 results
Start Over Author "Eyjolfsdottir B" Topic lymph nodes
2 results on '"Eyjolfsdottir B"'

1. Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe

Author

Kolk, W.L. van der, Zee, A.G.J. van der, Slomovitz, B.M., Baldwin, P.J.W., Doorn, H.C. van, Hullu, J.A. de, Velden, J. van der, Gaarenstroom, K.N., Slangen, B.F.M., Kjolhede, P., Brannstrom, M., Vergote, I., Holland, C.M., Coleman, R., Dorst, E.B.L. van, Driel, W.J. van, Nunns, D., Widschwendter, M., Nugent, D., DiSilvestro, P.A., Mannel, R.S., Tjiong, M.Y., Boll, D., Cibula, D., Covens, A., Provencher, D., Runnebaum, I.B., Monk, B.J., Zanagnolo, V., Tamussino, K., Oonk, M.H.M., Levenback, C.F., Hermans, R.H., Bouda, J., Sharma, A., Luesley, D., Ellis, P., Cruickshank, D.J., Duncan, T.J., Kieser, K., Palle, C., Spirtos, N.M., O'Malley, D.M., Leitao, M.M., Geller, M., Dhar, K., Asher, V., Tobias, D.H., Borgfeldt, C., Lea, J.S., Lood, M., Bailey, J., Eyjolfsdottir, B., Attard-Montalto, S., Tewari, K.S., Persson, P., Manchanda, R., Jensen, P., L. van le, GROINSS-V I II Participants, Obstetrie & Gynaecologie, MUMC+: MA Medische Staf Obstetrie Gynaecologie (9), RS: GROW - R2 - Basic and Translational Cancer Biology, Obstetrics and gynaecology, Amsterdam Reproduction & Development (AR&D), Targeted Gynaecologic Oncology (TARGON), Cancer Center Amsterdam, Obstetrics and Gynaecology, CCA - Cancer Treatment and Quality of Life, and Gynecological Oncology

Subjects
Lymphadenopathy, CANCER-PATIENTS, Groin, Humans, Science & Technology, Vulvar Neoplasms, Vulvar cancer, Radiotherapy, Sentinel Lymph Node Biopsy, Kirurgi, Obstetrics and Gynecology, Obstetrics & Gynecology, Women's cancers Radboud Institute for Health Sciences [Radboudumc 17], Oncology, Sentinel lymph node, Inguinofemoral lymphadenectomy, Lymph node metastases, Lymphatic Metastasis, Carcinoma, Squamous Cell, Lymph Node Excision, Surgery, Female, Lymph Nodes, Neoplasm Recurrence, Local, Life Sciences & Biomedicine
Abstract

Objective. Optimal management of the contralateral groin in patients with early-stage vulvar squamous cell carcinoma (VSCC) and a metastatic unilateral inguinal sentinel lymph node (SN) is unclear. We analyzed patients who participated in GROINSS-V I or II to determine whether treatment of the contralateral groin can safely be omitted in patients with a unilateral metastatic SN.Methods. We selected the patients with a unilateral metastatic SN from the GROINSS-V I and II databases. We determined the incidence of contralateral additional non-SN metastases in patients with unilateral SN-metastasis who underwent bilateral inguinofemoral lymphadenectomy (IFL). In those who underwent only ipsilateral groin treatment or no further treatment, we determined the incidence of contralateral groin recurrences during follow-up.Results. Of 1912 patients with early-stage VSCC, 366 had a unilateral metastatic SN. Subsequently, 244 had an IFL or no treatment of the contralateral groin. In seven patients (7/244; 2.9% [95% CI: 1.4%-5.8%]) disease was di-agnosed in the contralateral groin: five had contralateral non-SN metastasis at IFL and two developed an isolated contralateral groin recurrence after no further treatment. Five of them had a primary tumor >= 30 mm. Bilateral ra-diotherapy was administered in 122 patients, of whom one (1/122; 0.8% [95% CI: 0.1%-4.5%]) had a contralateral groin recurrence.Conclusion. The risk of contralateral lymph node metastases in patients with early-stage VSCC and a unilateral metastatic SN is low. It appears safe to limit groin treatment to unilateral IFL or inguinofemoral radiotherapy in these cases.(c) 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/). On behalf of all GROINSS-V I and II participants: C.F. Levenback, R.H. Hermans, J. Bouda, A. Sharma, D. Luesley, P. Ellis, D.J. Cruickshank, T.J. Duncan, K. Kieser,C. Palle, N.M. Spirtos, D.M. O'Malley, M.M. Leitao, M. Geller, K. Dhar, V. Asher, D.H. Tobias, C. Borgfeldt, J.S. Lea,M. Lood, J. Bailey, B. Eyjolfsdottir, S. Attard-Montalto, K.S. Tewari, P. Persson, R. Manchanda, P. Jensen, L. Van Le

Published
2022

2. Pelvic exenteration for vulvar cancer: Postoperative morbidity and oncologic outcome – A single center retrospective analysis.

Author

Valstad, H., Eyjolfsdottir, B., Wang, Y., Kristensen, G.B., Skeie-Jensen, T., and Lindemann, K.

Subjects
PELVIC exenteration, VULVAR cancer, LYMPH nodes, PATIENT selection, RETROSPECTIVE studies
Abstract

Pelvic exenteration may be the only curative treatment for some patients with primary advanced or recurrent vulvar cancer but is associated with high morbidity. This study evaluated the clinical outcome of patients treated at a centralized service in Norway. This retrospective study included patients treated with pelvic exenteration for primary locally advanced or recurrent vulvar cancer between 1996 and 2019 at Oslo University Hospital, Norway. Complications were coded according to the contracted Accordion classification. Relapse free survival (RFS), cancer specific survival (CSS) and overall survival (OS) were estimated with the Kaplan Meier method. The 30 patients were followed for a median of 4.94 years (95%CI: 3.37-NR). Exenteration due to primary vulvar cancer was carried out in 16 (53%) patients, 14 (47%) had recurrent vulvar cancer. Free histopathological margins were achieved in 28 (93%) patients. The 90 days morbidity for grade 3 complications was 63%, predominantly wound/surgical flap infections, 7% had no complications. 90 days mortality was 3%. Five-year RFS was 26% (95% CI 8–48%), OS was 50% (95%CI: 29–69%) and CSS was 64% (95% CI 43–79%). There was no significant difference in survival between patients with primary vs recurrent disease. The 3-year CSS for patients with negative lymph nodes and positive lymph nodes was 70% (95% CI 47–84%) and 30% (95% CI 1–72%), respectively. Acceptable oncologic outcomes after pelvic exenteration for primary and recurrent vulvar cancer can be achieved if surgery is centralized. Careful patient selection is imperative due to significant postoperative morbidity and considerable risk of relapse. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results